Abstract: The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.

Abstract: The invention relates to the use of electron active molecular crystals comprising tetrasilver tetroxide (Ag4O4) for the treatment and cure of dermatological skin conditions (diseases) ranging from dermatitis, acne and psoiasis to herpes and skin ulcers.

Abstract: The present invention generally relates to a composition useful for care of skin conditions and for skin protection and to a method for its preparation. The present invention further relates to a method for skin care and protection using said composition. More specifically, the present invention relates to a composition combining plant and algae extracts with water solutions from the Dead Sea especially useful for treating skin wrinkles and retaining skin moisture, to a method for the preparation thereof and to a method for skin care and protection comprising application of said composition.

Abstract: The first invention provides an external preparation for treating dermatoses comprising vitamin E and squalane, which has an efficacy at least equivalent to that of external preparations containing adrenocortical hormones as the active ingredient. The second invention provides an external preparation for treating dermatoses comprising an adrenocortical hormone, vitamin E and squalane, which is reduced in adrenocortical hormone content as compared with conventional preparations, is also reduced in side effects, and has high clinical efficacy. The third invention provides an external preparation for treating dermatoses comprising a nonsteroidal antiinflammatory agent, vitamin E and squalane and/or squalene, which is reduced in side effects and is highly efficacious. The fourth invention provides an external preparation for treating dermatoses comprising an antihistaminic agent, vitamin E and squalane and/or squalene, which is reduced in side effects and is highly efficacious like the above preparation.

Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Abstract: The present invention relates to a method of inhibiting angiogenesis in mammalian tissue which comprises supplying to the tissue a composition comprising an effective amount of epigallocatechin-gallate, epicatechin gallate or a combination thereof. The method is particularly useful in the treatment of angiogenesis-related skin conditions in which the catechin is applied topically, such as the treatment of various skin cancers, psoriasis, spider veins or undereye circles.

Abstract: A method is presented for treating hyperkeratotic diseases such as psoriasis which comprises applying a lysate of Halobacterium halobium to the effected skin area and irradiating with light. The preferred treatment involves multiple applications of a 2% composition of the lysate and irradiation for a period of twenty to sixty minutes with a 300 watt lamp.

Abstract: A composition for the maintenance of youthful, glowing, radiant, and hydrated skin, including a sufficient amounts of acids of hydroxacid, to facilitate exfoliation of skin in a novel moist manner, without substantial irritation, as well as the prevention, treatment and management of skin conditions, such as acne, wrinkled, irregularly pigmented, photoaged, and thickened layers of the epidermis, and the like, which has as major constituents, safflower oil, flaxseed oil, sweet almond oil, apricot kernel oil, jojoba oil, organic beeswax, stearic acid, cetearyl alcohol, a skin exfoliating agent, cocoa butter, vitamin A, tocopheral linoleate, borax, oil of lavender, and tincture of benzoin as an antimicrobial agent to inhibit or reduce microorganisms on the skin.

Abstract: A composition for the maintenance of smooth, radiant, hydrated skin, including sufficient amounts of acids of hydroxyacid, to facilitate exfoliation of skin in a novel manner, without substantial irritation, as well as the prevention, treatment and management of skin conditions, such as acne, wrinkled, irregularly pigmented, photoaged, and thickened layers of the epidermis, and the like, which has as its constituents, safflower oil, flaxseed oil, sweet almond oil, apricot kernel oil, jojoba oil, organic beeswax, stearic acid, cetearyl alcohol, cocoa butter, vitamin A and tocopheral linoleate, borax, oil of lavender, and tincture of benzoin as an antimicrobial agent.

Abstract: Hydrazine derivatives of the formula wherein Y is CO or SO2; R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y is SO2 and is lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-lower alkoxy or NR5R6 when Y is CO; and R3 is hydrogen, lower alkyl optionally substituted by cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; or R2 and R3 together form the residue of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulphonamide or cyclic urethane group; R4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula X-aryl, X-heteroar

Abstract: Cyclic peptide of formula (1) where Xaa1 is selected from L-amino acids selected from Phe, Lys and Arg, D-amino acids selected from Phe and Met, the L- and D-amino acid optionally substituted on its &agr;-carbon or its &agr;-amino group with a C1-4 alkyl group; and Melle; Xaa2, Xaa3 et Xaa4 are respectively Leu, Asp and Val, optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; X1 is selected from D-amino acids selected from Ala, Phe, Arg, Lys, Trp, hArg(Et)2, Orn(CHMe2), Orn(Me2), Lys(CHMe2) and Arg(Pmc), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; Formula (II); NH(CH2)5CO; and NH(CH2)2S(CH2)yCO, where y is 1 or 2; X2 is selected from D-amino acids selected from Ala, Arg, Lys, His, hArg(Et)2, Orm(CHMe2), and Om(Me2), optionally substituted on their &agr;-carbon or &agr;-amino group with a C1-4 alkyl group; NH(CH2)SCH2CO; and NH(CH2)xCO, where x is 2 or 3; Xaa5 and Xaa6 are each independently a

Abstract: This invention relates to the use of topically applied thyroid hormone compounds and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged kin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, corticosteroid atrophy, collagen deficient skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. The thyroid agonists and antagonists may also promote differentiation and amelioration of dedifferentiated skin in premalignant lesions.

Abstract: The topical application of formate to treat common skin ailments such as acne, alopecia, psoriasis, eczema, seborrhea, dermatitis, chronic itching, tinea infections, and insect bites.

Abstract: An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

Abstract: A description is given of new pharmaceutical compositions containing cyclosporine, combined with a carrier comprising at least a derivative of &agr;-glycerophosphoric acid, such as &agr;-glycerophosphorylcholine, &agr;-glycerophosphorylserine, &agr;-glycerophosphorylethanolamine and &agr;-glycerophosphoryl-myo-inositol, which allow cyclosporine bioavailability to significantly increase.

Abstract: A topical transdermal delivery system for lubricating and alleviating distressed skin conditions of the hands, and skin. It has as its constituents a mixture of organic safflower oil, flaxseed oil, tincture of benzoin, and organic beeswax blended in a cream-like base.

Abstract: The present invention provides a number of screening methods for evaluating compounds capable of suppressing cytokine production either in vitro or in vivo. The methods generally involve stimulating the production of a cytokine in a cell, exposing a portion of the cells to a putative cytokine modulating agent and determining subsequent levels of cytokine production in the cells. Additionally, the present invention provides certain compounds identified by this method.

Abstract: A compound effect for the treatment of dermatological disorders comprises a mono- or diester of an &agr;,&ohgr;-dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have the formula, where n is in the range of 6 to 12; m is in the range of 0 to 8; R′ is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR″, CONHR″ and COOR″; R″ is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

Abstract: The invention relates to the use of a) a compound or several compounds from the group consisting of flavonoids, or b) an active compound combination comprising a compound or several compounds chosen from the group consisting of flavonoids, in combination with a compound or several compounds chosen from the group consisting of cinnamic acid derivatives, and if appropriate additionally in each case a compound or several compounds from one of the groups or several of the groups c) of the antioxidants or d) of the endogenous energy metabolism metabolites or e) of the endogenous enzymatic antioxidant systems and synthetic derivatives thereof (mimics) or f) of the antimicrobial action systems or g) of the antiviral action systems or h) active compounds of the known, conventional treatment forms in each case for the treatment or prophylactic treatment of hyperreactive skin predisposed to dermatitis or deficient, hypoactive skin or dermatoses.

Abstract: A method of treating skin disorders using a extract from the plant Mullein (genus Verbascum) and a composition including an extract from the plant Mullein (genus Verbascum) are described. The extract is obtained by cooking the leaves and roots of the plant Mullein in a pressure cooker with water. The resulting liquid extract is canned according to standard home canning procedures. The method is accomplished by applying the liquid extract to affected areas of the skin twice daily. Most subjects experience positive results within a period of approximately two weeks. Skin disorders that have been treated using this extract include the sun exposure related skin disorders, actinic keratoses, lentigines, seborrheic keratoses, and the inflammatory skin disorders including prurigo, psoriasis, and contact dermatitis. The skin cancer, malignant melanoma, has also been treated using this method.

Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.

Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: Higher concentrations of oak bark ash extract, i.e., greater than 20% by weight, are useful for the treatment of skin cancers. Lower concentrations of oak bark extract possess additional therapeutic properties not heretofore recognized. For example, preparations containing 40-80% oak bark extract are useful in the treatment of acute cancerous skin ulcers. In addition, synthetic mixtures containing potassium ions, zinc ions, calcium ions provide many of the same advantageous properties of oak bark extract. The inclusion of rubidium ions and sulfur is also advantageous for some applications.

Abstract: The present invention provides compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase. The present invention also provides pharmaceutical compositions that contain a compound that inhibits the association of platelet-derived growth factor and phosphatidylinosital 3-kinase, and methods of treating cancer, restenosis, arthritis, dermatitis, atherosclerosis, vein graft intimal hyperplasia, neointimal hyperplasia of vascular smooth muscle and psoriasis using compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase.

Abstract: The invention relates to new phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.

Abstract: An herbal treatment composition is provided which includes Sarcandra glabra and a polysaccharide preferably derived from certain medicinal mushrooms. Methods for treating psoriasis and purpura using the composition are also disclosed.

Abstract: Bishydroxyureas are provided that inhibit the enzyme 5-lipoxygenase. These compounds have the formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and M are defined herein. Also disclosed are pharmaceutical compositions containing such compounds and methods of inhibiting the enzyme 5-lipoxygenase using such compounds.

Abstract: The present invention is directed to a topical composition for the treatment of psoriasis. The composition comprises a film forming agent, a plasticizer, an aqueous alcoholic solution and an amount of alkali effective to prevent the gellation of the film forming agent.

Abstract: This invention pertains to the novel combination of Vitamin E, evening primrose oil and B-complex vitamins as a treatment for patients afflicted with psoriasis. It is postulated that the above compounds act synergistically to provide the cofactors required for normal skin production and repair in psoriatic patients.

Abstract: The present invention is directed towards the control of inflammation. More specifically there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement.

Abstract: The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

Abstract: Vitamin D.sub.3 analogues of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or hydroxy, R.sub.2 is (C.sub.1 -C.sub.3)alkyl, hydroxy(C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.2)alkoxymethyl, (C.sub.2 -C.sub.3)alkenyl, or (C.sub.2 -C.sub.3)alkynyl, R.sub.3 is a branched or unbranched, saturated or unsaturated aliphatic 3- to 5- membered hydrocarbon or oxahydrocarbon biradical, having at least 3 atoms in the main chain and being optionally substituted with one or more substituents selected from epoxy, fluoro and hydroxy, R.sub.4 is sec. or tert. (C.sub.3 -C.sub.6)alkyl or (C.sub.3 -C.sub.6)cycloalkyl, A and B are each individually hydrogen or methyl, or A and B together from methylene.

Abstract: The present invention includes a process and composition for treating skin disorders. The composition of the present invention comprises 94.0 to 99.2 percent by weight of cation-free water, 0.1 to 1.0 percent by weight of Calcium chloride, 0.0 to 2.0 percent by weight of linear long chain polyphosphate, 0.1 to 1.0 percent by weight of sodium bicarbonate and 0.5 to 3.0 percent by weight of cross-linked polyacrylamide polymer.

Abstract: A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.

Abstract: A compound of the general formula (I): Q--R--X wherein Q is a substituted or unsubstituted furanyl, imidazolyl, pyrrolyl or thiopheneyl group, R is CR.sup.1.sub.2 --Cr.sup.2.sub.2, (cis)CR.sup.1 .dbd.CR.sup.2, or (trans)-CR.sup.1 .dbd.CR.sup.2, X is COOR.sup.3 or NR.sup.1 R.sup.4, and R.sup.1 -R.sup.4 are each, independently, H, an alkyl or an aryl group and pharmaceutically acceptable salts thereof, are described for use in topical treatments of skin conditions which involve an overactive immune response, or which are responsive to UV irradiation. Pharmaceutical compositions of the compound of general formula (I) are also described.

Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumoral, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being separated in a solid fraction (SOLID EXTRACT) and a liquid fraction which was further fractionated to obtain a LIQUID EXTRACT having molecules of a molecular weight comprised between 0 to 500 kDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components.

Abstract: An external skin treatment composition containing (I) vitamin A (retinol) and (II) as a stabilizer, a chelating agent/a polysaccharide, an oil, polyethylene (propylene) glycol, a hydroxy carboxylate, a neutral amino acid salt, an oil-soluble antioxidant/EDTA/a benzophenone compound, an oil-soluble antioxidant/an acid/a benzophenone compound, an inclusion compound of cyclodextrin including an antioxidant and/or an ultraviolet absorber, butanediol and/or an oil-soluble antioxidant, a water-soluble benzophenone compound, a basic amino acid and the salt thereof, an acidic amino acid and the salt thereof, a polar oil, a water-swellable clay mineral.

Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, direct anti-tumor proliferating, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being centrifuged and further fractionated to obtain a total extract having molecules of a molecular weight comprised between 0 to 500 KDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components. Due to the multiplicity of biological activities of the total liquid extract, it can be used for treating numerous diseases or conditions such as those having components selected from the group consisting of tumor proliferation, angiogenesis, inflammation and collagenolysis.

Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.

Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.

Abstract: The present invention provides compositions that inhibit apoptosis, methods for making the compositions, and methods of use thereof.

Abstract: The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.

Abstract: The invention provides methods of using photoactivated hypericin compounds which, when photoactivated using visible or UV-A light, are useful for treating numerous diseases and disorders in mammals. The compounds of the invention are useful for inhibiting the proliferation and accumulation of mammalian leukocytes and for inducing apoptosis in mammalian leukocytes.

Abstract: According to one embodiment of the topical therapeutic composition of the present invention, the composition comprises a combination of sulfur and Vitamin E in a range of about three parts of Vitamin E to one part sulfur to about equal parts of sulfur and Vitamin E. Preferably, the sulfur is in powder form, for example, sublimed sulfur, prior to mixing with the Vitamin E. The Vitamin E comprises either natural vitamin E (d-alpha tocopherol) or synthetic vitamin E (dl-alpha tocopherol) or a blend of both natural vitamin E (d-alpha tocopherol) and synthetic vitamin E (dl-alpha tocopherol).

Abstract: Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.

Abstract: The present invention relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma inducing factor (IGIF). The invention also relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma (IFN-.gamma.). The compositions comprise a therapeutically effective amount of a compound which inhibits interleukin-1.beta. converting enzyme (ICE) and a pharmaceutically acceptable carrier. The methods comprise the step of administering the above compositions to a subject. The present invention also relates to methods for treating or reducing the advancement, severity or effects of an IGIF- or IFN-.gamma.-mediated inflammatory, infectious or autoimmune condition.

Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: The present invention relates to shark cartilage extracts and to a method of producing the same, these extracts having anti-angiogenic properties (reduction of the area of blood vessels observed in vivo on experimentally induced tumors), tumor regressive activity in vivo as well as demonstrating a direct inhibitory effect on tumor cell lines. This process does not involve any denaturing solvent or product and does not involve the use of any enzymes. It consists of obtaining a blend of whole cartilage in an aqueous solution of neutral pH, preferably pure water, this blend being centrifuged and the pellet and supernatant kept for further processing. The pellet is lyophilized and tested for anti-tumor and anti-angiogenic activities in vivo and in vitro, with or without supernatant. The supernatant has been shown to have anti-angiogenic and tumor regressive activities in vivo. The composition of the supernatant has then been investigated by different ways.

Abstract: An active phospholipid of the formula ##STR1## wherein R.sub.1 is aliphatic of 14 to 24 carbon atoms saturated or containing 1 or 2 unsaturations, R.sub.3 is a residue selected from the group consisting of choline, ethanolamine, glycerol, serine, inositol, ethanol, n-propanol, n-butanol and ethylene glycol and ##STR2## is an active group in the 2-position of the glycerol released by phospholipases and cosmetic and dermatological compositions containing the same useful for treating or caring for the skin.

Abstract: Invented is a method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.